Cholinesterase inhibitor
Neostigmine metilsulfate
Injection (solution for injection) Neutigmin methyl sulfate 500 μg / ml, ampoule 1 ml; 2.5 mg / ml, ampoule 1 ml.
Uses: Antimicrobial effect of non-polarized muscle relaxants given during surgery; non-obstructive polyps retention after operation; muscular dystrophy and bile.
Contraindications: recent surgery on the intestine or bladder; mechanical obstruction in the intestine or urinary tract, after suxamethonium; pneumonia;
Asthma; urinary tract infections; cardiovascular disease, including arrhythmias (especially slow heart or ventricular occlusion); predominance of vagina; hypotension; peptic ulcer; epilepsy; Parkinsonism; Adequate (respiratory acidosis predisposes to system disorders); renal impairment (Appendix 4); pregnancy and breast feeding.
Dosage:
Followed by an intravenous catheter with intravenous injection over a minute, adult 2.5 mg, followed by necessary supplemental doses of 500 micrograms with a maximum total dose of 5 mg; child 40 micrograms per kg (calibrated with peripheral nerve stimulation).
Note: To reduce the carcinogenic effects, intravenous atropine sulfate (adult 0.6-1.2 mg, child 20 micrograms per kilogram) is given with or before neostigmine.
Postoperative urinary retention, by subcutaneous injection or intramuscular injection, ADULT 500 μg (catheterization is required if urinating within 1 hour).
Adverse effects: increased salivary and neuralgia, nausea and vomiting, stomach aches, diarrhea; allergic reactions, hypotension.
Neostigmine metilsulfate
Injection (solution for injection) Neutigmin methyl sulfate 500 μg / ml, ampoule 1 ml; 2.5 mg / ml, ampoule 1 ml.
Uses: Antimicrobial effect of non-polarized muscle relaxants given during surgery; non-obstructive polyps retention after operation; muscular dystrophy and bile.
Contraindications: recent surgery on the intestine or bladder; mechanical obstruction in the intestine or urinary tract, after suxamethonium; pneumonia;
Asthma; urinary tract infections; cardiovascular disease, including arrhythmias (especially slow heart or ventricular occlusion); predominance of vagina; hypotension; peptic ulcer; epilepsy; Parkinsonism; Adequate (respiratory acidosis predisposes to system disorders); renal impairment (Appendix 4); pregnancy and breast feeding.
Dosage:
Followed by an intravenous catheter with intravenous injection over a minute, adult 2.5 mg, followed by necessary supplemental doses of 500 micrograms with a maximum total dose of 5 mg; child 40 micrograms per kg (calibrated with peripheral nerve stimulation).
Note: To reduce the carcinogenic effects, intravenous atropine sulfate (adult 0.6-1.2 mg, child 20 micrograms per kilogram) is given with or before neostigmine.
Postoperative urinary retention, by subcutaneous injection or intramuscular injection, ADULT 500 μg (catheterization is required if urinating within 1 hour).
Adverse effects: increased salivary and neuralgia, nausea and vomiting, stomach aches, diarrhea; allergic reactions, hypotension.